February 4, 2021
Celgene’s CD19-targeting CAR-T cell therapy lisocabtagene maraleucel (liso-cel/JCAR017) will come up for discussion by a key health ministry advisory committee on February 17. If it clears the panel and gets approval, it would be the third product in the Japanese...read more